BridgeBio Pharma, Inc. (BBIO)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, BridgeBio Pharma, Inc. currently loses $16.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
BridgeBio Pharma’s third fiscal quarter of 2026 results topped consensus on EPS, with preliminary figures reported October 29, 2026 showing EPS of -$0.42 topping the -$0.54 estimate by $0.12. Revenue rose ~110% year over year to about $253.3 million (up from roughly $120.7 million a year ago), while net income narrowed to a loss of about $83.0 million, improving ~55% from a loss of roughly $182.7 million a year earlier alongside EPS improving ~56% from -$0.95. Profitability was reflected in gross profit of about $245.2 million and a gross margin near 97%. Cash generation remained negative, with negative operating cash flow of about $44.2 million, while the company reported repurchasing about $38.2 million of stock and paying roughly $2.7 million in dividends during the period. Consensus for the next period calls for EPS of -$0.53.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. is a NASDAQ-listed biotechnology company that develops medicines for genetic diseases, cancer-related conditions, and gene therapy applications. In FY2025, it generated $502.1 million of revenue. Founded in 2015 and based in Palo Alto, California, BridgeBio builds its business around a broad clinical pipeline and partnered research base.
Today's Snapshot
BBIO closed 1.6% above yesterday's close, outperforming a weaker sector. Volume was about a quarter more than its usual level.
Trading Volume
Above 10d avg 2.5M
3.5M
vs S&P 500 Today
Outperforming Market
+1.84%
Updated: November 18, 2026 at 21:08 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$72.57 - $76.95Buy
- RSI (14)62.39Neutral
- Stochastic %K (14, 3, 3)67.39Neutral
- MACD Level (12, 26)2.38Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.